

# Is protein the forgotten ingredient: effects of higher compared to lower protein diets on cardiometabolic risk factors. A systematic review and meta-analysis of randomised controlled trials

Article

Accepted Version

Vogtschmidt, Y. D., Raben, A., Faber, I., de Wilde, C., Lovegrove, J. A. ORCID: https://orcid.org/0000-0001-7633-9455, Givens, D. I. ORCID: https://orcid.org/0000-0002-6754-6935, Pfeiffer, A. F. H. and Soedamah-Muthu, S. S. (2021) Is protein the forgotten ingredient: effects of higher compared to lower protein diets on cardiometabolic risk factors. A systematic review and meta-analysis of randomised controlled trials. Atherosclerosis, 328. pp. 124-135. ISSN 0021-9150 doi: https://doi.org/10.1016/j.atherosclerosis.2021.05.011 Available at https://centaur.reading.ac.uk/102357/

It is advisable to refer to the publisher's version if you intend to cite from the work. See <u>Guidance on citing</u>.

To link to this article DOI: http://dx.doi.org/10.1016/j.atherosclerosis.2021.05.011

Publisher: Elsevier



All outputs in CentAUR are protected by Intellectual Property Rights law, including copyright law. Copyright and IPR is retained by the creators or other copyright holders. Terms and conditions for use of this material are defined in the <u>End User Agreement</u>.

# www.reading.ac.uk/centaur

# CentAUR

Central Archive at the University of Reading

Reading's research outputs online

#### **1** ATHEROSCLEROSIS

Is Protein the Forgotten Ingredient: Effects of Higher Compared to Lower Protein Diets
on Cardiometabolic Risk Factors – a Systematic Review and Meta-Analysis of
Randomised Controlled Trials

5 Yakima D. Vogtschmidt<sup>a, b, c, \*</sup>, Anne Raben<sup>d, e</sup>, Ilona Faber<sup>f</sup>, Claudia de Wilde<sup>g</sup>, Julie A.

6 Lovegrove<sup>a, b, c</sup>, D. Ian Givens<sup>b, c</sup>, Andreas F.H. Pfeiffer<sup>h, i</sup>, Sabita S. Soedamah-Muthu<sup>c, g</sup>

<sup>a</sup>Hugh Sinclair Unit of Human Nutrition, Harry Nursten Building, University of Reading, 7 Pepper Lane, Reading RG6 6DZ, United Kingdom; <sup>b</sup>Institute for Cardiovascular and Metabolic 8 Research, University of Reading, Reading RG6 6DZ, United Kingdom; <sup>c</sup>Institute for Food, 9 Nutrition and Health, University of Reading, Reading RG6 6AR, United Kingdom; 10 <sup>d</sup>Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, 11 Rolighedsvej 30, 1958 Frederiksberg C, Denmark; eSteno Diabetes Center Copenhagen 12 (SDCC), Niels Steensens Vej 2, 2820 Gentofte, Denmark; <sup>f</sup>Department of Food Science, 13 University of Copenhagen, Rolighedsvej 26, 1958 Frederiksberg C, Denmark; <sup>g</sup>Center of 14 Research on Psychological and Somatic disorders (CoRPS), Department of Medical and 15 Clinical Psychology, Tilburg University, 5000 LE Tilburg, the Netherlands; <sup>h</sup>German Center 16 for Diabetes Research, Partner Potsdam, Berlin, Germany; <sup>i</sup>Department of Endocrinology, 17 Diabetes and Nutrition, Campus Benjamin Franklin, Charité University of Medicine, 12200 18 Berlin, Germany. 19

20 \*Corresponding author:

Yakima D. Vogtschmidt. Hugh Sinclair Unit of Human Nutrition, Harry Nursten Building,
University of Reading, Pepper Lane, Reading RG6 6DZ, United Kingdom; Email:
<u>y.d.vogtschmidt@pgr.reading.ac.uk</u>

# 24 Total number of tables and figures: 6

# 25 **Email addresses of co-authors**

- 26 Professor Anne Raben
- 27 Email: <u>ara@nexs.ku.dk</u>
- 28 Ilona Faber, MSc.
- 29 Email: <u>ilona.faber@food.ku.dk</u>
- 30 Claudia de Wilde, MSc.
- 31 Email: <u>c.dewilde@prinsesmaximacentrum.nl</u>
- 32 Professor Julie Lovegrove
- 33 Email: j.a.lovegrove@reading.ac.uk
- 34 Professor Ian Givens
- 35 Email: <u>d.i.givens@reading.ac.uk</u>
- 36 Professor Andreas Pfeiffer
- 37 Email: <u>andreas.pfeiffer@charite.de</u>
- 38 Associate Professor Sabita Soedamah-Muthu
- 39 Email: <u>s.s.soedamah@tilburguniversity.edu</u>
- 40
- 41
- 42
- 43
- 44

45 Abstract

46

Background and aims: Higher protein (HP) diets may lead to lower cardiometabolic risk
compared to lower protein (LP) diets. This systematic review and meta-analysis aims to
investigate the effects of HP vs. LP diets on cardiometabolic risk factors in adults, using most
up-to-date evidence from randomised controlled trials (RCTs).

Methods: Systematic searches were conducted in electronic databases, up to November 2020.
Random effects meta-analyses were conducted to pool the standardised mean differences
(SMD) and 95% confidence intervals (CI). The main outcomes were weight loss, body mass
index (BMI), waist circumference, fat mass, systolic and diastolic BP, total cholesterol, HDLand LDL-cholesterol, triacylglycerol, fasting glucose and insulin, and glycated haemoglobin.

**Results:** Fifty-seven articles reporting on 54 RCTs were included, involving 4,344 participants 56 (65% female, mean age: 46 (SD 10) years, mean BMI: 33 (SD 3) kg/m<sup>2</sup>), with a mean study 57 duration of 18 weeks (range: 4 to 156 weeks). Compared to LP diets (range protein (E%):10-58 23%), HP diets (range protein (E%): 20-45%) led to more weight loss (SMD -0.13, 95% CI: -59 0.23, -0.03), greater reductions in fat mass (SMD -0.14, 95% CI: -0.24, -0.04), systolic BP 60 (SMD -0.12, 95% CI: -0.21, -0.02), total cholesterol (SMD -0.11, 95% CI: -0.19, -0.02), 61 triacylglycerol (SMD -0.22, 95% CI: -0.30, -0.14) and insulin (SMD -0.12, 95% CI: -0.22, -62 0.03). No significant differences were observed for the other outcomes. 63

64 Conclusions: Higher protein diets showed small, but favourable effects on weight loss, fat
65 mass loss, systolic blood pressure, some lipid outcomes and insulin, compared to lower protein
66 diets.

67

#### 69 Introduction

Dietary proteins are important sources of energy and essential amino acids, necessary for 70 71 various bodily processes, including tissue growth and maintenance [1]. The effects of dietary protein on human health are determined by several factors, including quantity, quality (animal 72 protein/plant protein) and source; animal (red and white meat, fish, eggs and dairy) or plant-73 74 based (nuts, legumes, grains). In terms of quantity, current European and US dietary recommendations for protein intake generally advise  $\geq 0.8$  g/kg body weight (BW)/day for 75 adults [2, 3] and growing evidence suggests an even higher intake for elderly (1.0-1.2 g/kg 76 BW/day) [4-6]. When expressed in percentage of the total energy intake (energy-percent 77 (E%)), the Nordic Nutrition Recommendations established a desirable daily protein intake of 78 10-20 E% for adults [7]. Other dietary guidelines provide similar recommendations, including 79 those from the UK [8], the Netherlands [9] and German-speaking countries (Germany, Austria 80 and Switzerland) [10]. 81

The impact of increasing dietary protein intake on cardiometabolic disease risk is still not 82 83 clearly defined and remains controversial. High protein diets have been promoted for decades for weight loss purposes, prevention of obesity and its metabolic consequences, yet have been 84 documented to increase the risk of cardiovascular disease (CVD) mortality [11, 12] and type 2 85 diabetes (T2D) [13]. High protein diets have been reported to promote atherogenesis in animal 86 87 models [14]. Mechanistically, protein ingestion acutely increases blood amino acid concentrations, circulating monocytes, and tissue macrophages, including those residing in the 88 atherosclerotic plaque. This, in turn, leads to acute elevation of macrophage mechanistic target 89 of rapamycin (mTOR) signalling, causing plaque progression [14]. High protein intake is also 90 91 reported to increase insulin-like growth factor-1 (IGF-1) and to activate the mTOR-S6 kinase 92 signalling pathway, while protein deficiency is sensed by unloaded transfer ribonucleic acid (tRNA) activating the protective general amino acid control nonderepressible-2 (GCN2) kinase 93

pathway which induces an activating transcription factor4 (ATF4) mediated protective
integrated stress response [15]. High protein intake, therefore, leads to proliferation and insulin
resistance in short lived animal and cell culture studies. Whether this applies to long living
species is uncertain, but there are epidemiological data suggesting that elevated protein intake
may be deleterious in younger people, but advantageous in older people [16, 17].

99 Prior meta-analyses of randomised controlled trials (RCTs) among adults suggest that higher protein (HP) diets may lead to improvements in weight loss and lower cardiometabolic risk, 100 compared to lower protein (LP) diets [18, 19]. Wycherley et al. (2012) conducted a meta-101 analysis of 24 RCTs (1,063 adults, mean study duration: 12 weeks) and found that high protein 102 diets (31 E%) led to more reductions in body weight (weighted mean difference (WMD) -0.79 103 kg), fat mass (WMD -0.87 kg), triacylglycerol concentrations (WMD -0.23 mmol/L) and a 104 105 significant increase in fat-free mass (WMD 0.43 kg), compared to standard protein diets (18 E%) [18]. However, this review only included energy restricted intervention studies and a 106 challenge with interpretation of these results is that energy restriction *per se* has a major impact 107 on appetite, energy intake, and body weight and thereby on markers of obesity, which limits 108 the ability to understand the independent effect of dietary protein. In addition, this review was 109 110 limited by heterogeneity of the study population which included both free-living and patient groups. Santesso et al. (2012) conducted a meta-analysis of 74 RCTs among free-living adults 111 112 with at least 5% difference in contribution from protein between the diets, without considering energy restriction [19]. Compared to the LP group (18 E%), the HP group (27 E%) 113 demonstrated greater reductions in body weight (standardised mean difference (SMD) -0.36), 114 BMI (SMD -0.37), waist circumference (SMD -0.43), blood pressure (systolic: SMD -0.21 and 115 diastolic: SMD -0.18) and triacylglycerol concentration (SMD -0.51) [19], but the effects were 116 considered small. However, this meta-analysis had relatively large heterogeneity for the 117 outcomes (range  $I^2$ : 42-85%) and included studies published prior to 2012 and studies with 118

very-low carbohydrate dietary interventions. The reported results from these types of diets may 119 lead to overestimation of the intervention effect, as very-low carbohydrate diets and the 120 associated higher intake of other macronutrients, such as saturated fatty acids (SFA) and lower 121 fibre intakes, may have an effect on cardiometabolic risk factors, independently of protein 122 intake (e.g. significant decreases in body weight and triacylglycerol concentration, significant 123 increases in total cholesterol, high-density lipoprotein-cholesterol (HDL-c) and low-density 124 125 lipoprotein-cholesterol (LDL-c)) [20]. Since the 2012 review [19], fourteen studies have been published on the effect of HP compared to LP diets on various cardiometabolic risk factors 126 127 (e.g. body weight, blood pressure, lipid outcomes) [21-34]. Therefore, a renewed analysis with up-to-date evidence is warranted. 128

The present systematic review and meta-analysis aims to evaluate the effects of HP vs. LP diets
on a wide range of cardiometabolic risk factors in adults from the general population, using the
totality of the current evidence from RCTs.

# 132 Materials and methods

This study was conducted according to the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) guidelines [35]. A protocol for this systematic review and metaanalysis was not previously published.

# 136 Search strategy

Literature searches were conducted in PubMed, Web of Science and Scopus, in addition to
checking of reference lists of retrieved articles and previously published meta-analyses [18, 19,
36, 37]. The searches involved a range of keywords for dietary protein, body weight and
anthropometrics, body composition, blood pressure, blood lipids, markers of glucose
metabolism and trial design. A detailed search strategy can be found in Supplementary table

All English language studies that met the eligibility criteria were selected, up to November
 2020.

#### 144 Eligibility criteria

RCTs among adults  $\geq$ 18 years with no presence of chronic medical conditions (including T2D, 145 CVD, kidney diseases), as described by papers, were included. Trials also met the following 146 criteria to be eligible for inclusion: 1) intervention consisted of provision of foods or dietary 147 advice for a higher protein (HP) diet; 2) the comparator consisted of provision of foods or 148 dietary advice for a lower protein (LP) diet; 3) duration of study was at least 4 weeks; 4) one 149 of the following outcomes was assessed: body weight (weight loss), anthropometrics (body 150 mass index (BMI), waist circumference), body composition (fat mass), blood pressure (systolic 151 blood pressure (SBP), diastolic blood pressure (DBP)), fasting blood concentrations of lipids 152 (plasma or serum total cholesterol, HDL-c, LDL-c, triacylglycerol concentrations), markers of 153 glucose metabolism (fasting plasma/serum glucose and insulin, glycated haemoglobin 154  $(HbA_{1c})).$ 155

A predefined difference in contribution of at least 3 E% from protein between the HP and LP 156 157 diets was chosen, with HP diets being at least 3 E% higher than LP diets, a minimum contrast in protein intake between the diets as suggested by the Health Council of the Netherlands [9]. 158 Data on the mean dietary protein intakes at the end of the intervention were considered as it 159 160 represented the treatment intakes over the entire study period. Protein needed to be consumed 161 from foods. For this reason, trials in which protein supplements or meal replacements were used were excluded. Furthermore, studies that compared very-low carbohydrate diets (<25 E% 162 163 from carbohydrate) with high carbohydrate diets were excluded as well as studies with cointerventions e.g. structured exercise programmes or high intensity resistance training. 164

#### 166 Study selection and data extraction

Sourced articles were imported into ENDNOTE X9 and Covidence Online Software [38]. The titles and abstracts were screened by three independent reviewers (IF, CDW and YDV) to check for eligibility criteria, with discrepancies resolved by consensus. If multiple publications were identified on the same trial, only data of the original publications were included.

Data were extracted by YDV and independently double-checked by IF and CDW, with 171 inconsistencies resolved by consensus. Data were independently extracted using Covidence 172 and a predesigned form that included author name, publication year, study design, country 173 undertaken, studied outcomes, sample size, participant characteristics, intervention 174 characteristics, dietary characteristics, study duration and context, reporting of urine urea or 175 nitrogen data (yes/no), reporting of power calculation (yes/no) and funding source. Means, 176 177 standard deviations (SD), standard errors (SE) or 95% confidence intervals (CI) of the change from baseline values, baseline values and postintervention values were extracted. Graphed data 178 were extracted using WebPlotDigitizer version 4.4 [39]. 179

For trials involving multiple arms, only data from the most relevant intervention and 180 181 comparison group were extracted. For crossover trials, only data of the period before crossover were considered to avoid any carry-over effects due lack of reporting on washout period 182 between the dietary phases within the crossover trials [40, 41]. If the intervention of a trial 183 184 involved a weight loss period followed by a weight maintenance period, then data from the end of the weight maintenance period were extracted. Only data at the end of the intervention were 185 extracted in which food intake were precisely measured and reported [42, 43]. If results from 186 187 both per-protocol-analysis and intention-to-treat analysis (ITT) were reported, then data from the ITT were extracted. SI conversion factors were used: To convert cholesterol to mmol/L, 188 mg/dl were multiplied by 0.0259; to convert triacylglycerols to mmol/L, mg/dl were multiplied 189

by 0.0113; to convert glucose to mmol/L, mg/dl were multiplied by 0.0555; to convert fasting insulin to pmol/L,  $\mu$ IU/mL were multiplied by 6.

#### 192 Risk of bias within studies

To evaluate the methodological quality of the individual studies, the Cochrane Collaboration's revised tool was used to assess the risk of bias in the randomised trials (RoB 2.0) [44]. The RoB 2.0 consists of 5 domains for the assessment of individual randomised trials: randomisation process, deviations from intended interventions, missing outcome data, measurement of the outcome and selection of the reported result.

### 198 Data analysis

The mean difference in the outcomes between the intervention and control group were 199 calculated as standardised mean difference (SMD) and weighted mean difference (WMD) with 200 95% CI. The SMD and WMD were calculated based on mean and SD of the change from 201 202 baseline values. If not reported, then these were calculated using the reported data. The mean<sub>change</sub> was calculated by subtracting the baseline values from the postintervention values. 203 The SD<sub>change</sub> was calculated using the following formula; SD<sub>change</sub> =  $\sqrt{(SD_{baseline}^2 +$ 204  $SD_{postintervention}^{2}$ ) – (2 x r x  $SD_{baseline}$  x  $SD_{postintervention}$ ) [45], where r represented the correlation 205 coefficient between the baseline and postintervention values and was assumed to be 0.5 and 206 led to more conservative estimates (wider 95% CI). 207

Random-effects models were carried out to pool the data of RCTs, which examined the effects of HP compared to LP diets on changes in weight loss, weight regain, BMI, waist circumference, fat mass, lean mass, SBP, DBP, total cholesterol, HDL-c, LDL-c, triacylglycerol, glucose, insulin, HOMA-IR and HbA<sub>1c</sub>, accounting for within and between study variance [46]. Between-study heterogeneity was evaluated using the I<sup>2</sup> statistic (%) [47], where I<sup>2</sup> of  $\leq$ 30%, between 30% and 50%, between 50% and 75% and  $\geq$ 75% were considered, representing low, moderate, substantial and considerable heterogeneity, respectively [45]. The overall effect estimates of the trials in the meta-analysis models were presented in the forest plots, stratified by SD<sub>change</sub> reported or obtained from standard errors or confidence intervals and SD<sub>change</sub> imputed using a correlation coefficient.

Sensitivity analysis was performed to assess the influence of excluding trials that were judged to be at high risk of bias. Heterogeneity between the studies was analysed using subgroup analyses on sex, age (<50 years vs.  $\geq 50$  years) and study duration (<12 weeks vs. 12 weeks-24 weeks vs.  $\geq 24$  weeks). Multivariate meta-regression analyses were conducted to investigate the influence of weight loss on the effect of HP compared to LP diets on outcomes for which significant results were found, including fat mass, SBP, total cholesterol, triacylglycerol, and insulin.

Risk of publication bias for each outcome were assessed visually and quantitatively using funnel plots and Egger's weighted regression test [48], respectively. Trim and fill method was used [49], if evidence for publication bias was found. Analyses were performed in Stata Statistical Software version 15.0 and two-sided p at 0.05 were considered to be statistically significant in the analyses.

#### 230 **Results**

# 231 **3.1 Study selection process**

A total of 7,104 records were initially identified, of which 6,951 were excluded after title and abstract screening (**Figure 1**). Thirty-one duplicates were removed, leaving 122 full text articles. Of these, 57 articles reporting on 54 RCTs were included in the meta-analyses, excluding 65 articles. More detailed information on the study selection process can be found in **Figure 1**.

#### 238 **3.2 Study characteristics**

The characteristics of the 54 RCTs are described in **Supplementary table 2**. The studies evaluated a total of 4,344 participants and the percentage of women was 65% (**Supplementary table 3**). The mean (SD) age and BMI were 46 (10) y (range: 23 to 70 y) and 33 (3) kg/m<sup>2</sup> (range: 24 to 39 kg/m<sup>2</sup>), respectively (**Supplementary table 3**).

Of the 54 RCTs included, 51 were parallel trials and 3 had a cross-over design (**Supplementary table 3**). The mean (SD) study duration was 18 (23) weeks (range: 4 to 156 weeks). Trials were conducted in North America (n=26), Australia and Oceania (n=14), Europe (n=10), Asia (n=3) or Europe, Australia, and New Zealand (n=1). The mean (SD) dropout rate or loss to followup was 17 (17) % (range: 0-70%). Thirty-five out of 54 trials did not receive funding from an industrial source (**Supplementary table 3**).

The achieved relative intake of dietary protein, carbohydrate, and total fat (E%) were, on average, 28% (range: 20 to 45%), 41% (range: 25 to 55%) and 31% (range: 20 to 43%) in the HP group and 18% (range: 10 to 23%), 54% (range: 36 to 66%) and 28% (range: 20 to 45%) in the LP group (**Supplementary table 3**). The mean (SD) total daily energy intakes were 1,764 (455) kcal and 1,768 (462) kcal in the HP and LP groups, respectively (**Supplementary table 3**).

#### **3.3 Changes in body weight, anthropometrics, and body composition**

A total of 48 trials with 3,346 participants provided data on weight loss, 3 on weight regain (774 participants), 27 on BMI (2,012 participants) and 26 on waist circumference (2,669 participants). Meta-analysis revealed statistically significant effects on weight loss with HP compared to LP diets, with a pooled SMD of -0.13 (95% CI: -0.23, -0.03). There was moderate to low heterogeneity across the trials ( $I^2 = 38\%$ , p=0.004) (**Figure 2**). This is equivalent to an increase in weight loss of 0.64 kg (95% CI: -1.12, -0.17,  $I^2 = 53\%$ , p=0.000) with HP compared

to LP diets. Significant intervention effects were observed for weight loss when the participants 262 were under 50 years of age, with a pooled SMD of -0.17 (95% CI: -0.31, -0.03) 263 (Supplementary table 5). The meta-analysis also revealed less weight regain in the HP 264 compared to LP groups (pooled SMD -0.18, 95% CI: -0.32, -0.04,  $I^2 = 0\%$ , p=0.6) 265 (Supplementary table 4). However, removal of Larsen et al. (2010) from the analysis, a trial 266 contributing most weight to the pooled estimate, attenuated the results for weight regain 267 (pooled SMD -0.08, 95% CI: -0.39, 0.24,  $I^2 = 0\%$ , p=0.5). The pooled analyses across trials 268 showed a tendency towards an effect in favour of the HP diet for a lower BMI (pooled SMD -269 0.11, 95% CI: -0.23, 0.01,  $I^2 = 31\%$ , p=0.1) and waist circumference (pooled SMD -0.11, 95% 270 CI: -0.23, 0.01,  $I^2 = 44\%$ , p=0.006), but these were not statistically significant (Supplementary 271 table 4). 272

Meta-analysis of 35 trials with 2,580 participants showed a significant reduction in fat mass 273 with HP compared to LP diets (pooled SMD -0.14, 95% CI: -0.24, -0.04). There was low 274 heterogeneity across the trials ( $I^2 = 28\%$ , p=0.1) (Figure 3). The pooled WMD for reduction 275 in fat mass was 0.55 kg (95% CI: -0.92, -0.17,  $I^2 = 28\%$ , p=0.1) in favour of the HP diet. 276 Significant intervention effects were found for fat mass when participants were 50 years of age 277 or older (pooled SMD -0.15, 95% CI: -0.26, -0.03) (Supplementary table 5). Meta-analysis 278 of 30 trials involving 2,418 participants showed no significant differences between the diets 279 for lean mass (pooled SMD 0.06, 95% CI: -0.06, 0.17,  $I^2 = 39\%$ , p=0.013) (Supplementary 280 table 4). 281

282 **3.4 Changes in blood pressure** 

A total of 26 trials with 1,813 participants provided data for the meta-analysis for SBP and DBP. A reduction in SBP and DBP was found with HP compared to LP diets (pooled SMD -0.12, 95% CI: -0.21, -0.02,  $I^2 = 0.0\%$ , *p*=0.9) (**Figure 4**) and (pooled SMD -0.09, 95% CI: -0.19, 0.01,  $I^2 = 9\%$ , p=0.3) (**Supplementary table 4**), respectively, although this did not reach statistical significance for DBP. The pooled WMD for reduction in SBP was 1.16 mm Hg (95% CI: -2.13, -0.20,  $I^2=0\%$ , p=0.8) with HP compared to LP diets. The intervention effects were borderline significant for SBP when participants were under 50 years of age (pooled SMD -0.12, 95% CI: -0.23, -0.00) (**Supplementary table 5**) and the study duration was under 12 weeks (pooled SMD -0.15, 95% CI: -0.30, -0.00) (**Supplementary table 6**).

# 292 **3.5 Changes in blood lipid concentrations**

A total of 41 trials (2,303 participants) reported data on total cholesterol, 42 trials (2,452 293 participants) on HDL-c, 42 trials (2,516 participants) on LDL-c and 43 trials (2,530 294 participants) on triacylglycerol. Meta-analysis demonstrated a reduction in total cholesterol 295 with HP compared to LP diets (pooled SMD -0.11, 95% CI: -0.19, -0.02) (Figure 5a). Results 296 were consistent across all 41 trials with low heterogeneity ( $I^2 = 1\%$ , p=0.5). No significant 297 differences between the diets were observed for HDL-c (pooled SMD 0.10, 95% CI: 0.01, 0.20, 298  $I^2 = 19\%$ , p=0.1) or LDL-c (pooled SMD 0.01, 95% CI: -0.08, 0.10,  $I^2 = 20\%$ , p=0.1). A 299 significant reduction in triacylglycerol was found with HP compared to LP diets (pooled SMD 300 -0.22, 95% CI: -0.30, -0.14) and pooled trial data for this outcome was homogeneous ( $I^2 = 0\%$ , 301 p=0.9) (Figure 5b). Translated to an effect in clinical units, a greater reduction in total 302 cholesterol of 0.08 mmol/L (95% CI: -0.13, -0.03,  $I^2=0\%$ , p=0.5) and a greater reduction in 303 triacylglycerol of 0.12 mmol/L (95% CI: -0.16, -0.08,  $I^2=0\%$ , p=0.8) was observed with HP 304 compared to LP diets. Significant intervention effects were observed for total cholesterol when 305 participants were 50 years of age or older (pooled SMD -0.16, 95% CI: -0.29, -0.02) 306 307 (Supplementary table 5) and the study duration was under 12 weeks (pooled SMD -0.25, 95%) CI: -0.40, -0.09) (Supplementary table 6). For triacylglycerol, the intervention effects were 308 significant when participants were female (pooled SMD -0.25, 95% CI: -0.40, -0.11) 309 (Supplementary table 7), the study duration was under 12 weeks (pooled SMD -0.32, 95% 310

311 CI: -0.46, -0.18) and between 12 and 24 weeks (pooled SMD -0.20, 95% CI: -0.31, -0.08) but
312 not when it was 24 weeks or longer (Supplementary table 6).

### 313 **3.6 Changes in markers of glucose metabolism**

Thirty-four trials (2,592 participants) were included in the meta-analysis on glucose, 28 trials 314 (2,270 participants) with data on insulin, 19 trials (1,674 participants) on HOMA-IR and 3 315 trials (152 participants) on HbA<sub>1c</sub>. Pooled analysis showed a statistically significant lowering 316 effect of HP diets on insulin, compared to LP diets (pooled SMD -0.12, 95% CI: -0.22, -0.03), 317 with low heterogeneity across the trials ( $I^2 = 13\%$ , p=0.3) (Figure 6). Significant intervention 318 effects of the were observed for insulin when participants were female (pooled SMD -0.37, 319 95% CI: -0.58, -0.17) (Supplementary table 7), and in the subgroup of 50 years of age or 320 older (pooled SMD -0.15, 95% CI: -0.27, -0.02) (Supplementary table 5). No significant 321 differences between the diets were found for glucose (pooled SMD -0.01, 95% CI: -0.11, 0.12, 322  $I^2 = 43\%$ , p=0.003), HOMA-IR (pooled SMD -0.05, 95% CI: -0.22, 0.11,  $I^2 = 56\%$ , p=0.001) 323 or HbA<sub>1c</sub> (pooled SMD -0.02, 95% CI: -0.49, 0.45,  $I^2 = 52\%$ , p=0.1) (Supplementary table 324 **4**). 325

# 326 **3.7 Sensitivity analyses**

Removal of Keogh et al. (2007) [50], a study judged to be high risk of bias, from the analysesdid not change the overall effect estimates of the outcome measures.

# 329 **3.8 Meta-regression analyses**

Multivariate meta-regression analysis showed no major influence of body weight change on
the observed association between dietary protein intake and the outcome measures
(Supplemental table 5).

#### 334 **3.9** Risk of bias within and between studies

The overall risk of bias of the included trials ranged from 'low' to 'some concerns' and 'high'. 335 Most trials showed concerns about the selection of the reported result due to not publishing 336 details on the pre-specified analysis plans and the randomisation process (e.g., sequence 337 concealment) (Supplementary Figure 1). Only 1 of 54 trials demonstrated high risk of bias 338 339 [50] (Supplementary Figure 1). Assessment of the risk of bias of the included trials can be found in Supplementary table 6. No evidence for publication bias was found in the meta-340 analyses for the outcomes, except for triacylglycerol (Egger's test p=0.0) (Supplementary 341 figures 2-7). However, trim and fill analyses revealed no major change in the observed overall 342 effect estimate (pooled SMD -0.14, 95% CI: -0.21, -0.07). 343

~

#### 344 **Discussion**

345

The present systematic review and meta-analyses of 54 RCTs have shown favourable but small 346 effects of HP vs. LP diets on weight loss, fat mass, SBP, total cholesterol, triacylglycerol, and 347 fasting insulin among adults over a mean follow-up of 4-5 months. Findings of these meta-348 analyses suggest that intake of higher dietary protein (28 E%) (range: 20-45%) compared to 349 lower dietary protein (18 E%) (range: 10-23%) could lead to more weight loss and reductions 350 351 in fat mass, SBP, total cholesterol, triacylglycerol, and fasting insulin. No significant differences between the diet were found for BMI, waist circumference, lean mass, HDL-c, and 352 LDL-c, DBP, glucose, HbA<sub>1c</sub> and insulin resistance estimated by HOMA-IR. 353

354 Comparison with other reviews

Previous systematic reviews and meta-analyses that compared the effect of higher vs. lower protein diets, irrespective of the source of protein, on various health outcomes generally support our results [18, 19, 51]. Our findings suggest that higher protein diets can lead to improvements

in weight loss [18, 19] and reduction in fat mass [18], compared to lower protein diets. There 358 was no clear effect on BMI and waist circumference, which is in contrast with the meta-analysis 359 by Santesso et al. (2012) [19], who found small to moderate effects. Apart from more studies 360 and participants included in our meta-analysis, we also excluded trials that were included in 361 Santesso's review. This involved very-low carbohydrate dietary interventions, very low-fat and 362 low-fat or high-fat dietary comparisons and studies with co-interventions, which could explain 363 364 part of the discrepancies. Surprisingly, there was no effect on lean body mass, which is in contrast with the meta-regression by Krieger et al. (2006) [52], who included single arms from 365 366 observational studies and RCTs, and previous meta-analyses, which only considered energyrestricted dietary interventions [18, 53]. In terms of blood pressure, significant effects were 367 observed of HP diets lowering SBP, but not on DBP, which is partly in line with previous 368 studies [19, 51], who found beneficial effects on both SBP and DBP. In line with previous 369 studies, we found greater reduction in triacylglycerol with HP vs. LP diets, with no significant 370 differences in HDL-c and LDL-c [18, 19]. However, we observed a borderline significant lower 371 total cholesterol after HP compared to LP diets. In terms of diabetes related outcomes, our 372 study suggests no clear effects of HP diets on glucose and HbA<sub>1c</sub>, which is in line with previous 373 studies [18, 19, 36]. However, we did observe small improvements in fasting insulin with HP 374 compared to LP diets, in line with previous publications [36, 37]. 375

376 Possible explanations

Several lines of evidence have suggested potential mechanisms underlying the effect of dietary protein intake on changes in intermediary CVD risk factors. An increase in dietary protein intake may prevent weight regain and obesity [54]. It is suggested that higher protein intake during energy restriction or energy balance may have beneficial effect on body weight loss and subsequent weight maintenance [55]. The negative energy balance is a result of decreased energy intake and increased energy expenditure, which can be explained by the satiating effects

of protein and preservation of fat-free mass (FFM), respectively [55]. Furthermore, dietary 383 protein, irrespective of the type, may also have a blood-pressure lowering effect [56]. There is 384 evidence which demonstrates that bioactive peptides can inhibit the activity of angiotensin 385 converting enzyme (ACE), a key component of the renin-angiotensin system (RAS), that 386 mediates systemic hypertension. The ACE-inhibitory activity and peptides have been observed 387 from protein isolates e.g. whey protein isolates [57, 58] and from other food sources e.g. dairy, 388 389 fish, meat, egg products, soybeans, rice and nuts [59]. The link between dietary protein intake and blood lipid concentrations is more limited. A crossover RCT among healthy men and 390 391 women revealed that a high protein, high fat hypercaloric diet significantly changed body composition, lowered intrahepatic lipids and circulating triacylglycerol concentrations, 392 compared to a standard protein diet [60]. In addition, previous studies reported effective 393 394 lowering of cholesterol concentrations with diets that included lean beef as a major protein source [61-63]. Previous double-blinded randomised, 3 way-crossover intervention study 395 investigating the impact of intact milk protein supplementation have found that whey protein 396 and calcium-caseinate intakes decreased total cholesterol, but only whey protein reduced 397 triacylglycerol, compared to the controls [57]. A systematic review that compared the effects 398 of animal vs. plant protein sources on features of metabolic syndrome indicated that soy protein 399 (with isoflavones), but not soy protein alone or other plant proteins, led to greater lowering in 400 total cholesterol and LDL-c, compared to animal-sourced protein [64]. This is partly supported 401 402 by findings of a meta-analysis of 112 RCTs that showed that substitution of animal protein by plant protein led to reductions in LDL-c, non-HDL-c and ApoB [65]. Dietary proteins may 403 have lipid lowering effects, which may be dependent on the food source, although the exact 404 405 underlying mechanisms still need to be determined.

406

An important strength of this systematic review and meta-analysis is the standard systematic 409 410 methodology used in the identification, selection, reporting, synthesis, and interpretation of the studies. An elaborated predefined search syntax was used, and data were independently 411 extracted using predefined forms and verified by multiple reviewers. Our review is the most 412 413 comprehensive on this topic using the most up-to-date literature. Another strength is the inclusion of many trials with low between-study heterogeneity and little to no evidence for 414 publication bias. Trial data for our outcomes were relatively more homogenous compared to 415 data used by Santesso et al. (2012) [19], with I<sup>2</sup> varying between 0% and 56%. This may be 416 due to very-low carbohydrate studies that were excluded from our review but were included in 417 Santesso's analyses. Another strength is that this meta-analysis is based on RCTs across 418 various populations with varying health statuses (e.g., healthy people, people with overweight, 419 obesity, hypertension, hyperinsulinemia, hyperlipidaemia, metabolic syndrome (MetS), 420 polycystic ovary syndrome and prediabetes), representing real-life situations. Additionally, we 421 used a careful approach to calculate the change-from-baseline SD for the study outcomes, 422 resulting in lower effect sizes, which were presented separately in the forest plots. The separate 423 424 presentation of imputed and reported SD was performed previously [19] and showed similar effect sizes. 425

This systematic review and meta-analysis also has several limitations, which include the relatively limited data available to evaluate the effect of dietary protein intake on weight regain, HOMA-IR and HbA<sub>1c</sub>. Another limitation is that it is difficult to determine whether the effects of higher protein diets are due to protein or the reductions in other macronutrients, including carbohydrate or fats, although we made every attempt to control for this by excluding trials with very-low carbohydrate dietary interventions and trials with very low-fat and low-fat or high-fat dietary comparisons. Another limitation of this study is the inclusion of intermediary

outcomes, not hard clinical outcomes, although these outcomes play an important role in the 433 development of diseases. To date, limited studies with trial design have been conducted on the 434 435 effects of higher protein intake on hard clinical outcomes in high-risk populations [66, 67]. Previous evidence from the PREDIMED Study in people at high risk of CVD demonstrated 436 that Mediterranean diets, supplemented with either extra-virgin olive oil or nuts, similarly 437 reduced CVD risk by approximately 30% [66] and T2D risk by 50% [67] compared with the 438 439 control diet, after follow-up for at least 4 years. Recently, results on T2D incidence in the PREVIEW Study have been reported after follow-up for 3 years [68]. The authors found no 440 441 difference in the 3-year incidence in T2D between an ad-libitum high protein, low-GI diet and an ad libitum moderate protein, moderate-GI diet, in participants with prediabetes [68], which 442 could be explained by the large and fast initial weight loss (which was still partially present 443 after 3 years) [68]. More RCTs are needed that investigate the long-term effects of higher vs. 444 lower protein diets on incidence of type 2 diabetes and CVD-associated events in high-risk 445 populations. In addition, the results of this meta-analysis may not be generalized to other 446 populations such as people with chronic diseases. A recently published 3-month randomised 447 controlled study among 76 overweight and obese patients with heart failure and diabetes 448 mellitus (72.4% male, mean age: 57.7 years) have shown that high protein diets (30 E%) led to 449 significantly greater reductions in HbA<sub>1c</sub> levels, total cholesterol and triacylglycerol 450 concentrations, SBP and DBP, compared to standard protein diets (15 E%) [69]. These findings 451 suggest that a HP diet may be more effective in lowering cardiometabolic risk in these 452 populations. Another limitation is that the SDs were not always reported in the publications. If 453 these were reported, then the effect sizes would most likely be more precise. Furthermore, we 454 were not able to investigate the effects of protein from different food sources on our outcomes 455 due to lack of reporting of intake of the main source of protein in most of the articles. A re-456 analysis of the DIOGENES Study suggests potential differential effects of protein from 457

different sources on weight maintenance and cardiometabolic risk factors [70], but moreresearch is needed in this area.

#### 460 *Context and implications for future research*

The present systematic review and meta-analysis of 54 RCTs in adults demonstrated that HP 461 diets compared to LP diets had small but favourable effects on weight loss, fat mass loss, 462 systolic blood pressure and some lipid outcomes, which are relevant markers for CVD risk. 463 Decreases in fasting insulin was also observed with HP compared to LP diets, but the effect 464 was small. The amount of dietary protein in HP and LP diets in this meta-analysis is according 465 to the Acceptable Macronutrient Distribution Range (AMDR) for protein, which is 10%-35% 466 of the total energy intake [2], except for one RCT [71]. Our results suggest that a modest 467 increase in the proportion of dietary protein within the diets may have, small but beneficial 468 469 effects on intermediary risk factors of CVD. Future high quality RCTs are needed that focus on the effects of HP diets on weight regain and diabetes related outcomes (e.g. insulin 470 471 resistance and HbA<sub>1c</sub>). Future studies should also investigate the effectiveness of HP compared to LP diets in people with chronic diseases. More research is also needed on the potential 472 differential effects of protein from specific food sources on cardiometabolic risk factors. 473

Our study showed that a higher protein diet had no detrimental effects and some beneficial
effects, although these were clinically small. Future work is needed on the long-term effects of
a higher protein diet on cardiometabolic risk factors and hard clinical outcomes.

#### 478 **Conflict of interest**

YDV received funding from the Rank Prize Funds, the Dutch Dairy Association and the Danish
Dairy Research Foundation. The funding sources were not involved in the study design, the
collection, analyses, and interpretation of data and in the writing of the report. All the other
authors declare no conflict of interest.

#### 483 Author contributions

YDV, AR, AFHP and SSSM conceived and designed the review. YDV, IF and CDW performed the literature search and screened the data. YDV extracted the data. IF and CDW verified the extracted data. YDV analysed and interpreted the data. SSSM supervised YDV with data analyses and interpretation. YDV wrote the draft manuscript. AR, AFHP, JAL, DIG and SSSM critically revised the manuscript for important intellectual content. All authors gave final approval of the version to be submitted and any revised version.

# 490 Acknowledgements

491 The authors thank Dr. Andrew Reynolds from the University of Otago, New Zealand, for his 492 statistical advice and for provision of information on the Cochrane Risk of Bias tool 2.0. The 493 authors thank the Rank Prize Funds, the Dutch Dairy Association and the Danish Dairy 494 Research Foundation for funding the research.

495

496

497

#### 499 **References**

500 [1] Wu G (2016) Dietary protein intake and human health. Food Funct 7(3): 1251-1265.
501 10.1039/c5fo01530h

Institute of Medicine (2005) Dietary reference intakes for energy, carbohydrate, fiber,
fat, fatty acids, cholesterol, protein, and amino acids. In. Institute of Medicine, Washington DC
European Food Safety Authority Panel on Dietetic Products NaAN (2012) Scientific
opinion on dietary reference values for protein: Dietary reference value for protein. EFSA
Journal 10(2): 2557. 10.2903/j.efsa.2012.2557

507 [4] Deutz NE, Bauer JM, Barazzoni R, et al. (2014) Protein intake and exercise for optimal
508 muscle function with aging: recommendations from the ESPEN Expert Group. Clin Nutr 33(6):
509 929-936. 10.1016/j.clnu.2014.04.007

510 [5] Houston DK, Nicklas BJ, Ding J, et al. (2008) Dietary protein intake is associated with
511 lean mass change in older, community-dwelling adults: the Health, Aging, and Body
512 Composition (Health ABC) Study. Am J Clin Nutr 87(1): 150-155. 10.1093/ajcn/87.1.150

513 [6] Dorrington N, Fallaize R, Hobbs DA, Weech M, Lovegrove JA (2020) A Review of
514 Nutritional Requirements of Adults Aged ≥65 Years in the UK. J Nutr 150(9): 2245-2256.
515 10.1093/jn/nxaa153

516 [7] Nordic Council of Ministers (2014) Nordic Nutrition Recommendations 2012517 Integrating nutrition and physical activity. In: Nord Nutr Recomm 2014. Vol 5

518[8]Public Health England (2016) Government Dietary Recommendations-Government

recommendations for energy and nutrients for males and females aged 1-18 years and 19+

520 years. In. Public Health England, London, United Kingdom

521 [9] Health Council of the Netherlands (2015) Protein-Background document of the Dutch

522 dietary guidelines 2015. In. Health Council of the Netherlands, The Hague

- 523 [10] Richter M, Baerlocher K, Bauer JM, et al. (2019) Revised Reference Values for the
  524 Intake of Protein. Ann Nutr Metab 74(3): 242-250. 10.1159/000499374
- 525 [11] Chen Z, Glisic M, Song M, et al. (2020) Dietary protein intake and all-cause and cause-
- 526 specific mortality: results from the Rotterdam Study and a meta-analysis of prospective cohort
- 527 studies. Eur J Epidemiol 35(5): 411-429. 10.1007/s10654-020-00607-6
- 528 [12] Zhong VW, Van Horn L, Greenland P, et al. (2020) Associations of Processed Meat,
- 529 Unprocessed Red Meat, Poultry, or Fish Intake With Incident Cardiovascular Disease and All-
- 530 Cause Mortality. JAMA Intern Med 180(4): 503-512. 10.1001/jamainternmed.2019.6969
- 531 [13] Tian S, Xu Q, Jiang R, Han T, Sun C, Na L (2017) Dietary Protein Consumption and
- the Risk of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Cohort Studies.
- 533 Nutrients 9(9). 10.3390/nu9090982
- 534 [14] Zhang X, Sergin I, Evans TD, et al. (2020) High-protein diets increase cardiovascular
- risk by activating macrophage mTOR to suppress mitophagy. Nat Metab 2(1): 110-125.
  10.1038/s42255-019-0162-4
- 537 [15] Maida A, Zota A, Sjoberg KA, et al. (2016) A liver stress-endocrine nexus promotes
  538 metabolic integrity during dietary protein dilution. J Clin Invest 126(9): 3263-3278.
  539 10.1172/JCI85946
- [16] Levine ME, Suarez JA, Brandhorst S, et al. (2014) Low Protein Intake Is Associated
  with a Major Reduction in IGF-1, Cancer, and Overall Mortality in the 65 and Younger but
  Not Older Population. Cell Metab 19(3): 407-417. 10.1016/j.cmet.2014.02.006
- 543 S1550-4131(14)00062-X [pii]
- 544 [17] Mittendorfer B, Klein S, Fontana L (2020) A word of caution against excessive protein
  545 intake. Nat Rev Endocrinol 16(1): 59-66. 10.1038/s41574-019-0274-7
- 546 [18] Wycherley TP, Moran LJ, Clifton PM, Noakes M, Brinkworth GD (2012) Effects of
- 547 energy-restricted high-protein, low-fat compared with standard-protein, low-fat diets: a meta-

- 548 analysis of randomized controlled trials. Am J Clin Nutr 96(6): 1281-1298.
  549 10.3945/ajcn.112.044321
- [19] Santesso N, Akl EA, Bianchi M, et al. (2012) Effects of higher- versus lower-protein
  diets on health outcomes: a systematic review and meta-analysis. Eur J Clin Nutr 66(7): 780788. 10.1038/ejcn.2012.37
- [20] Harvey C, Schofield GM, Zinn C, Thornley SJ, Crofts C, Merien FLR (2019) Lowcarbohydrate diets differing in carbohydrate restriction improve cardiometabolic and
  anthropometric markers in healthy adults: A randomised clinical trial. PeerJ 7: e6273.
  10.7717/peerj.6273
- 557 [21] Azadbakht L, Izadi V, Surkan PJ, Esmaillzadeh A (2013) Effect of a High Protein
  558 Weight Loss Diet on Weight, High-Sensitivity C-Reactive Protein, and Cardiovascular Risk
  559 among Overweight and Obese Women: A Parallel Clinical Trial. Int J Endocrinol 2013:
  560 971724. 10.1155/2013/971724
- [22] Bales CW, Starr KNP, Orenduff MC, et al. (2017) Influence of Protein Intake, Race,
  and Age on Responses to a Weight-Reduction Intervention in Obese Women. Current
  Developments in Nutrition 1(5). 10.3945/cdn.117.000703
- [23] Bray GA, Smith SR, Jonge Ld, et al. (2012) Effect of dietary protein content on weight
  gain, energy expenditure, and body composition during overeating. Journal of the American
  Medical Association 307(1): 47-55
- 567 [24] González-Salazar LE, Pichardo-Ontiveros E, Palacios-González B, et al. (2020) Effect
  568 of the intake of dietary protein on insulin resistance in subjects with obesity: a randomized
  569 controlled clinical trial. Eur J Nutr. 10.1007/s00394-020-02428-5
- 570 [25] Griffin HJ, Cheng HL, O'Connor HT, Rooney KB, Petocz P, Steinbeck KS (2013)
  571 Higher protein diet for weight management in young overweight women: a 12-month
  572 randomized controlled trial. Diabetes, Obesity and Metabolism 15(6): 572-575

573 [26] Jenkins DJ, Wong JM, Kendall CW, et al. (2014) Effect of a 6-month vegan low-574 carbohydrate ('Eco-Atkins') diet on cardiovascular risk factors and body weight in 575 hyperlipidaemic adults: a randomised controlled trial. BMJ Open 4(2): e003505. 576 10.1136/bmjopen-2013-003505

577 [27] Kim I-Y, Schutzler SE, Azhar G, Wolfe RR, Ferrando AA, Coker RH (2017) Short 578 term elevation in dietary protein intake does not worsen insulin resistance or lipids in older 579 adults with metabolic syndrome: a randomized-controlled trial. BMC nutrition 3. 580 10.1186/s40795-017-0152-4

581 [28] Mateo-Gallego R, Marco-Benedí V, Perez-Calahorra S, et al. (2017) Energy-restricted,

high-protein diets more effectively impact cardiometabolic profile in overweight and obese

583 women than lower-protein diets. Clin Nutr 36(2): 371-379. 10.1016/j.clnu.2016.01.018

[29] Porter Starr KN, Pieper CF, Orenduff MC, et al. (2016) Improved Function With
Enhanced Protein Intake per Meal: A Pilot Study of Weight Reduction in Frail, Obese Older
Adults. J Gerontol A Biol Sci Med Sci 71(10): 1369-1375. 10.1093/gerona/glv210

[30] Raben A, Vestentoft PS, Brand-Miller J, et al. (2020) The PREVIEW intervention
study: Results from a 3-year randomized 2 x 2 factorial multinational trial investigating the
role of protein, glycaemic index and physical activity for prevention of type 2 diabetes.
Diabetes Obes Metab. 10.1111/dom.14219

[31] Tang M, Armstrong CL, Leidy HJ, Campbell WW (2013) Normal vs. high-protein
weight loss diets in men: effects on body composition and indices of metabolic syndrome.
Obesity (Silver Spring) 21(3): E204-210. 10.1002/oby.20078

[32] Witjaksono F, Jutamulia J, Annisa NG, Prasetya SI, Nurwidya F (2018) Comparison of
low calorie high protein and low calorie standard protein diet on waist circumference of adults
with visceral obesity and weight cycling. BMC research notes 11(1): 674-674.
10.1186/s13104-018-3781-z

- 598 [33] Wright CS, Jing Z, Sayer RD, Jung Eun K, Campbell WW (2018) Effects of a high-
- 599 protein diet including whole eggs on muscle composition and indices of cardiometabolic health
- and systemic inflammation in older adults with overweight or obesity: a randomized controlled
- trial. Nutrients 10(7): 946-946. 10.3390/nu10070946
- 602 [34] Wycherley TP, Brinkworth GD, Clifton PM, Noakes M (2012) Comparison of the
- 603 effects of 52 weeks weight loss with either a high-protein or high-carbohydrate diet on body
- 604 composition and cardiometabolic risk factors in overweight and obese males. Nutr Diabetes
- 605 2(8): e40. 10.1038/nutd.2012.11
- 606 [35] Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for
- 607 systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7): e1000097.
- 608 10.1371/journal.pmed.1000097
- 609 [36] Schwingshackl L, Hoffmann G (2013) Long-term effects of low-fat diets either low or
- 610 high in protein on cardiovascular and metabolic risk factors: a systematic review and meta-
- 611 analysis. Nutr J 12: 48. 10.1186/1475-2891-12-48
- 612 [37] Clifton PM, Condo D, Keogh JB (2014) Long term weight maintenance after advice to
- 613 consume low carbohydrate, higher protein diets--a systematic review and meta analysis. Nutr
- 614 Metab Cardiovasc Dis 24(3): 224-235. 10.1016/j.numecd.2013.11.006
- 615 [38] Covidence systematic review software (2020) Covidence. Available from
  616 https://www.covidence.org/
- 617 [39] Rohatgi A (2020) WebPlotDigitalizer Version 4.4. Available from
  618 https://automeris.io/WebPlotDigitizer. Accessed November 2020
- [40] Jenkins DJ, Kendall CW, Vidgen E, et al. (2001) High-protein diets in hyperlipidemia:
- effect of wheat gluten on serum lipids, uric acid, and renal function. Am J Clin Nutr 74(1): 57-
- 621 63. 10.1093/ajcn/74.1.57

- 622 [41] Tura A, Conte B, Caparrotto C, et al. (2010) Insulin sensitivity and secretion in young,
- healthy subjects are not changed by Zone and Mediterranean diets. Mediterranean Journal of
  Nutrition and Metabolism 3(3): 233-237
- 625 [42] Aldrich ND, Reicks MM, Sibley SD, Redmon JB, Thomas W, Raatz SK (2011)
- 626 Varying protein source and quantity do not significantly improve weight loss, fat loss, or satiety
- 627 in reduced energy diets among midlife adults. Nutrition Research 31(2): 104-112
- 628 [43] Due A, Toubro S, Skov AR, Astrup A (2004) Effect of normal-fat diets, either medium
- or high in protein, on body weight in overweight subjects: a randomised 1-year trial. Int J Obes
- 630 Relat Metab Disord 28(10): 1283-1290. 10.1038/sj.ijo.0802767
- 631 [44] Sterne JAC, Savović J, Page MJ, et al. (2019) RoB 2: a revised tool for assessing risk
- 632 of bias in randomised trials. Bmj 366: 14898. 10.1136/bmj.14898
- [45] Higgins JP, Green S (2011) Cochrane Handbook for Systematic Reviews of
  Interventions Version 5.1.0. In. The Cochrane Collaboration
- [46] DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials
  7(3): 177-188. 10.1016/0197-2456(86)90046-2
- [47] Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in
  meta-analyses. Bmj 327(7414): 557-560. 10.1136/bmj.327.7414.557
- Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis
  detected by a simple, graphical test. Bmj 315(7109): 629-634. 10.1136/bmj.315.7109.629
- 641 [49] Duval S, Tweedie R (2000) Trim and fill: A simple funnel-plot-based method of testing
- and adjusting for publication bias in meta-analysis. Biometrics 56(2): 455-463. 10.1111/j.0006-
- 643 341x.2000.00455.x
- 644 [50] Keogh JB, Brinkworth GD, Clifton PM (2007) Effects of weight loss on a low-
- 645 carbohydrate diet on flow-mediated dilatation, adhesion molecules and adiponectin. Br J Nutr
- 646 98(4): 852-859. 10.1017/s0007114507747815

647 [51] Altorf-van der Kuil W, Engberink MF, Brink EJ, et al. (2010) Dietary protein and blood
648 pressure: a systematic review. PLoS One 5(8): e12102. 10.1371/journal.pone.0012102

[52] Krieger JW, Sitren HS, Daniels MJ, Langkamp-Henken B (2006) Effects of variation

650 in protein and carbohydrate intake on body mass and composition during energy restriction: a

651 meta-regression 1. Am J Clin Nutr 83(2): 260-274. 10.1093/ajcn/83.2.260

[53] Kim JE, O'Connor LE, Sands LP, Slebodnik MB, Campbell WW (2016) Effects of
dietary protein intake on body composition changes after weight loss in older adults: a
systematic review and meta-analysis. Nutr Rev 74(3): 210-224. 10.1093/nutrit/nuv065

[54] Larsen TM, Dalskov SM, van Baak M, et al. (2010) Diets with high or low protein
content and glycemic index for weight-loss maintenance. N Engl J Med 363(22): 2102-2113.
10.1056/NEJMoa1007137

[55] Drummen M, Tischmann L, Gatta-Cherifi B, Adam T, Westerterp-Plantenga M (2018)
Dietary Protein and Energy Balance in Relation to Obesity and Co-morbidities. Front
Endocrinol (Lausanne) 9: 443. 10.3389/fendo.2018.00443

[56] Tielemans SM, Altorf-van der Kuil W, Engberink MF, et al. (2013) Intake of total 661 protein, plant protein and animal protein in relation to blood pressure: a meta-analysis of 662 observational and intervention studies. J Hum Hypertens 27(9): 564-571. 10.1038/jhh.2013.16 663 Fekete Á A, Giromini C, Chatzidiakou Y, Givens DI, Lovegrove JA (2016) Whey [57] 664 protein lowers blood pressure and improves endothelial function and lipid biomarkers in adults 665 with prehypertension and mild hypertension: results from the chronic Whey2Go randomized 666 controlled trial. Am J Clin Nutr 104(6): 1534-1544. 10.3945/ajcn.116.137919 667

1007 controlled that. All J Chil Nutr 104(0): 1534-1544. 10.5945/ajcii.110.157919

669 inhibitory effects of tryptophan-containing peptides from whey protein hydrolysate in healthy

Martin M, Hagemann D, Nguyen TT, et al. (2020) Plasma concentrations and ACE-

670 volunteers. Eur J Nutr 59(3): 1135-1147. 10.1007/s00394-019-01974-x

668

[58]

- [59] Xue L, Yin R, Howell K, Zhang P (2021) Activity and bioavailability of food proteinderived angiotensin-I-converting enzyme-inhibitory peptides. Compr Rev Food Sci Food Saf.
  10.1111/1541-4337.12711
- [60] Rietman A, Schwarz J, Blokker BA, et al. (2014) Increasing Protein Intake Modulates
- 675 Lipid Metabolism in Healthy Young Men and Women Consuming a High-Fat Hypercaloric
- 676 Diet. The Journal of Nutrition 144(8): 1174-1180. 10.3945/jn.114.191072
- [61] Melanson K, Gootman J, Myrdal A, Kline G, Rippe JM (2003) Weight loss and total
- 678 lipid profile changes in overweight women consuming beef or chicken as the primary protein
- 679 source. Nutrition 19(5): 409-414. 10.1016/s0899-9007(02)01080-8
- 680 [62] Scott LW, Dunn JK, Pownall HJ, et al. (1994) Effects of beef and chicken consumption
- on plasma lipid levels in hypercholesterolemic men. Arch Intern Med 154(11): 1261-1267
- 682 [63] Davidson MH, Hunninghake D, Maki KC, Kwiterovich PO, Jr., Kafonek S (1999)
- 683 Comparison of the effects of lean red meat vs lean white meat on serum lipid levels among684 free-living persons with hypercholesterolemia: a long-term, randomized clinical trial. Arch
- 685 Intern Med 159(12): 1331-1338. 10.1001/archinte.159.12.1331
- [64] Chalvon-Demersay T, Azzout-Marniche D, Arfsten J, et al. (2017) A Systematic
  Review of the Effects of Plant Compared with Animal Protein Sources on Features of
  Metabolic Syndrome. J Nutr 147(3): 281-292. 10.3945/jn.116.239574
- [65] Li SS, Blanco Mejia S, Lytvyn L, et al. (2017) Effect of Plant Protein on Blood Lipids:
- 690 A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc
- 691 6(12). 10.1161/jaha.117.006659
- 692 [66] Estruch R, Ros E, Salas-Salvadó J, et al. (2018) Primary Prevention of Cardiovascular
- 693 Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. N Engl
- 694 J Med 378(25): e34. 10.1056/NEJMoa1800389

- [67] Salas-Salvadó J, Bulló M, Babio N, et al. (2011) Reduction in the incidence of type 2
  diabetes with the Mediterranean diet: results of the PREDIMED-Reus nutrition intervention
  randomized trial. Diabetes Care 34(1): 14-19. 10.2337/dc10-1288
- [68] Raben A, Vestentoft PS, Brand-Miller J, et al. (2021) The PREVIEW intervention
  study: Results from a 3-year randomized 2 x 2 factorial multinational trial investigating the
  role of protein, glycaemic index and physical activity for prevention of type 2 diabetes.
  Diabetes Obes Metab 23(2): 324-337. 10.1111/dom.14219
- 702 [69] Evangelista LS, Jose MM, Sallam H, et al. (2021) High-protein vs. standard-protein
- diets in overweight and obese patients with heart failure and diabetes mellitus: findings of the
- Pro-HEART trial. ESC Heart Fail. 10.1002/ehf2.13213
- 705 [70] van Baak MA, Larsen TM, Jebb SA, et al. (2017) Dietary Intake of Protein from
- 706 Different Sources and Weight Regain, Changes in Body Composition and Cardiometabolic
- Risk Factors after Weight Loss: The DIOGenes Study. Nutrients 9(12). 10.3390/nu9121326
- 708 [71] Baba NH, Sawaya S, Torbay N, Habbal Z, Azar S, Hashim SA (1999) High protein vs
- high carbohydrate hypoenergetic diet for the treatment of obese hyperinsulinemic subjects. Int
- 710 J Obes Relat Metab Disord 23(11): 1202-1206. 10.1038/sj.ijo.0801064

711

# 713 Keywords

714 Cardiometabolic; Meta-analysis; Protein diet; Randomised controlled trial; Systematic review


# 715 Abbreviations


716	ACE	Angiotensin converting enzyme

- 717 AMDR Acceptable macronutrient distribution range
- 718 ATF4 Activating transcription factor 4
- 719 BMI Body mass index
- 720 BP Blood pressure
- 721 BW Body weight
- 722 CI Confidence interval
- 723 CVD Cardiovascular disease
- 724 DBP Diastolic blood pressure
- 725E%Energy percent
- 726FGF21Fibroblast growth factor 21
- 727 FFM Fat free mass
- 728
   GCN2
   General amino acid control nonderepressible-2
- 729 HbA<sub>1c</sub> Glycated haemoglobin
- 730 HDL-c High density lipoprotein cholesterol
- 731 HOMA-IR Homeostatic model assessment of insulin resistance
- 732 HP Higher protein

733	IGF-1	Insulin-like growth factor 1
-----	-------	------------------------------

- 734 ITT Intention-to-treat
- 735 LDL-c Low density lipoprotein cholesterol
- 736 LP Lower protein
- 737 MetS Metabolic syndrome
- 738 mTOR Mechanistic target of rapamycin
- 739 RAS Renin-angiotensin system
- 740 RCT Randomised controlled trial
- 741 SBP Systolic blood pressure
- 742 SD Standard deviation
- 743 SE Standard error
- 744 SFA Saturated fatty acids
- 745 SMD Standardised mean difference
- 746 tRNA Transfer ribonucleic acid
- 747 T2D Type 2 diabetes
- 748 UK United Kingdom
- 749 US United States
- 750 WMD Weighted mean difference
- 751
- 752





sub and author	Intervention Control year N Mean (SD) N Mean (SD)		% SMD (95% CI) Weight
			Gine (60 % Gr) Weight
Change-from-baseline SD reported or obtained from Baba	n standard errors or confidence intervals 1999 7 -8.30 (1.85) 6 -6.00 (1.47)		-1.36 (-2.59, -0.13) 1.07
Farnsworth	2003 28 -7.80 (3.70) 28 -7.90 (3.17)		0.03 (-0.49, 0.55) 3.31
Luscombe-Marsh	2003 17 -7.90 (4.54) 19 -8.00 (3.05)		0.03 (-0.63, 0.68) 2.63
Aude	2004 22 -6.20 (1.80) 23 -3.40 (2.90)		-1.15 (-1.79, -0.52) 2.73
Due	2004 23 -9.40 (5.09) 23 -5.90 (4.05) 2004 9 -4.68 (1.48) 7 -4.61 (1.03)		-0.76 (-1.36, -0.16) 2.90
Johnston Stamets	2004 9 -4.68 (1.48) 7 -4.61 (1.03) 2004 13 -3.70 (1.90) 13 -4.40 (1.50)		-0.05 (-1.04, 0.93) 1.52 0.41 (-0.37, 1.19) 2.13
Dansinger	2005 40 -3.80 (3.60) 40 -3.50 (3.80)	<b>=</b>	-0.08 (-0.52, 0.36) 3.85
Luscombe-Marsh (male population)	2005 12 -10.50 (5.89) 13 -11.20 (6.13)		0.12 (-0.67, 0.90) 2.10
Luscombe-Marsh (female population)	2005 15 -7.80 (3.21) 17 -7.90 (5.36)		0.02 (-0.67, 0.72) 2.45
Noakes McMillan-Price	2005 52 -7.60 (2.88) 48 -6.90 (3.46) 2006 33 -4.40 (2.87) 32 -4.80 (2.83)		-0.22 (-0.61, 0.17) 4.15
Das	2006 33 -4.40 (2.87) 32 -4.80 (2.83) 2007 14 -6.08 (3.90) 15 -6.28 (3.22)		0.14 (-0.35, 0.63) 3.54 0.06 (-0.67, 0.78) 2.31
Gardner	2007 79 -2.14 (2.40) 79 -2.74 (2.67)	· <b></b>	0.24 (-0.08, 0.55) 4.72
Keogh	2007 8 -4.60 (5.94) 5 -5.50 (2.68)		0.18 (-0.94, 1.30) 1.25
Leidy	2007 21 -8.10 (1.83) 25 -9.50 (5.00)	_ ++	0.36 (-0.23, 0.94) 2.97
Mahon Maki	2007 14 -6.60 (2.70) 14 -5.60 (1.80)		-0.44 (-1.19, 0.31) 2.23
Lasker	2007 42 -4.90 (3.24) 42 -2.50 (3.24) 2008 25 -9.10 (4.50) 25 -6.90 (4.00)		-0.74 (-1.18, -0.30) 3.82 -0.52 (-1.08, 0.05) 3.09
Abete	2009 9 -8.33 (1.26) 10 -4.98 (2.99)	<b>_</b>	-1.43 (-2.45, -0.41) 1.44
Layman	2009 52 -9.30 (7.21) 51 -7.40 (4.28)		-0.32 (-0.71, 0.07) 4.18
Sacks	2009 202 -3.86 (14.21) 204 -3.00 (14.28)		-0.08 (-0.25, 0.13) 5.51
Belobrajdic	2010 34 -9.27 (3.60) 42 -8.08 (3.27) 2011 6 -5.90 (1.45) 6 -5.30 (1.86)		-0.35 (-0.80, 0.11) 3.73
Aldrich Te Morenga	2011 6 -5.90 (1.45) 6 -5.30 (1.86) 2011 37 -4.50 (2.55) 37 -3.30 (2.70)		-0.38 (-1.50, 0.78) 1.21 -0.48 (-0.92, 0.00) 3.70
Wycherley	2012 33 -10.20 (4.90) 35 -9.40 (4.40)		-0.17 (-0.65, 0.30) 3.60
Griffin	2013 36 -6.90 (10.94) 35 -3.50 (5.09)	<b>B?</b>	-0.40 (-0.87, 0.07) 3.64
Tang	2013 22 -9.10 (3.28) 21 -10.60 (2.75)		0.49 (-0.11, 1.10) 2.86
Porter-Starr Balan	2016 41 -8.70 (7.40) 26 -7.50 (6.20) 2017 51 -6.20 (5.30) 29 -6.40 (4.90)		-0.17 (-0.66, 0.32) 3.50 0.04 (-0.42, 0.49) 3.73
Bales Mateo-Gallego	2017 51 -6.20 (5.30) 29 -6.40 (4.90) 2017 29 -8.49 (4.64) 24 -7.05 (3.61)		0.04 (-0.42, 0.49) 3.73 -0.34 (-0.89, 0.20) 3.19
Wright	2018 12 -2.31 (0.65) 10 -3.83 (0.72)		- 2.23 (1.14, 3.31) 1.31
Raben	2020 235 -4.98 (8.19) 240 -5.18 (5.80)		0.03 (-0.15, 0.21) 5.60
Subgroup, DL	1273 1244	A	-0.15 (-0.29, -0.01)100.00
(l <sup>^</sup> = 59.4%, p = 0.000)			
Change-from-baseline SD imputed using a correlation	ion coefficient		
Jenkins	2001 10 0.00 (9.65) 10 0.00 (9.80)		0.00 (-0.88, 0.88) 2.43
Layman	2003 12 -3.86 (12.99) 12 -3.22 (10.46)		-0.05 (-0.85, 0.75) 2.91
Moran Mamo	2003 14 -8.50 (4.12) 14 -6.90 (2.99) 2005 10 -1.30 (3.55) 10 -0.70 (5.66)		-0.44 (-1.20, 0.31) 3.31 -0.13 (-1.00, 0.75) 2.42
Ferrara	2005 10 -1.30 (3.55) 10 -0.70 (5.66) 2006 7 -2.00 (7.55) 8 -0.70 (12.53)		-0.13 (-1.00, 0.75) 2.42 -0.12 (-1.14, 0.89) 1.81
Hodgson	2006 29 0.20 (16.66) 31 0.10 (15.30)		0.01 (-0.50, 0.51) 7.27
Kleiner	2006 9 -4.90 (20.26) 7 -4.00 (17.89)		-0.05 (-1.03, 0.94) 1.91
De Luis	2007 47 -4.50 (15.15) 43 -3.60 (18.00)		-0.05 (-0.47, 0.38) 10.90
Meckling De Luis (wild type group)	2007 10 -4.60 (13.60) 8 -2.10 (8.11) 2009 85 -4.20 (18.52) 87 -3.70 (17.10)		-0.22 (-1.15, 0.72) 2.14 -0.03 (-0.33, 0.27) 20.87
De Luis (wild type group) De Luis (mutant type group)	2009 12 -6.00 (21.62) 9 -2.90 (15.86)		-0.16 (-1.03, 0.71) 2.49
De Luis	2009 52 -3.40 (19.90) 66 -4.00 (17.67)		0.03 (-0.33, 0.40) 14.12
Ballesteros-Pomar (people with insulin resistance)	2010 10 -7.90 (14.77) 11 -8.10 (13.18)		0.01 (-0.84, 0.87) 2.54
Ballesteros-Pomar (people without insulin resistance			-0.22 (-1.24, 0.80) 1.80
Azadbakht Jenkins	2013 30 -6.10 (5.77) 30 -3.93 (8.22) 2014 20 -6.80 (11.70) 19 -5.00 (13.73)		-0.31 (-0.81, 0.20) 7.20 -0.14 (-0.77, 0.49) 4.72
Kim	2017 6 -0.70 (16.66) 6 0.00 (25.84)		-0.03 (-1.16, 1.10) 1.46
González-Salazar (animal protein intervention)	2020 20 -3.56 (18.56) 19 -3.60 (14.89)		0.00 (-0.63, 0.63) 4.73
González-Salazar (plant protein intervention)	2020 20 -3.60 (28.12) 21 -4.05 (12.98)		0.02 (-0.59, 0.63) 4.97
Subgroup, DL	411 418	9	-0.07 (-0.21, 0.07) 100.00
(l <sup>*</sup> = 0.0%, p = 1.000)			
Overall, DL	1684 1662	•	-0.13 (-0.23, -0.03)
Heterogeneity between groups: p = 0.395		Ť	
(1 <sup>2</sup> = 37.7%, p = 0.004)			
		-1.5 -1 -0.5 0 0.5 1 1.5	
		Favours higher protein diet Favours lower protein diet	

Figure 2. Standardised mean difference (SMD) and 95% confidence interval (CI) in weight loss between the intervention and control groups on the effect of a higher protein diet.

sub and author	year	N	Intervention Mean (SD)	N	Control Mean (SD)									SMD (95% CI)	% Weight
Change-from-baseline SD reported or o Farnsworth (male population) Farnsworth (female population) Due Johnston Luscombe-Marsh (male population) Luscombe-Marsh (female population) Noakes McMillan-Price Leidy Mahon Maki Lasker Abete Delbridge Layman Belobrajdic Tura Aldrich Goyenechea Te Morenga Bray Wycherley	2003 2003 2004 2004 2005 2005 2005 2005 2006 2007 2007 2007 2007 2008 2009 2009 2009 2010 2010 2010	from : 7 21 23 9 12 33 21 14 52 33 21 14 37 9 68 52 34 6 6 6 124 34 8 30	-9.00 (7.14) -6.60 (6.42) -7.60 (4.28) -2.76 (2.05) -5.60 (4.16) -4.30 (3.10) -5.70 (4.33) -3.70 (2.87) -6.60 (1.83) -4.30 (2.10) -1.90 (1.82) -6.00 (3.00) -5.72 (1.06) 7.00 (1.72) 6.60 (5.05) -6.86 (4.00) -1.00 (3.00) -5.17 (1.22) -0.92 (7.39) 1.4.00 (1.72) 3.44 (1.00)	7 21 23 7 12 16 48 32 25 14 37 25 10 70 51 42 6 6	onfidence intervals -7.60 (8.20) -7.10 (9.17) -4.30 (3.12) -3.05 (1.07) -5.90 (3.97) -4.80 (4.95) -4.50 (2.83) -6.60 (3.00) -3.90 (1.50) -0.90 (1.82) -4.40 (2.50) -3.56 (2.02) -6.60 (10.88) 4.90 (2.86) -5.46 (4.16) -2.00 (1.00) -4.29 (1.71) -0.69 (6.75) -2.50 (2.81) 3.45 (1.02) -5.70 (4.00)		•							-0.18 (-1.23, 0.8 0.06 (-0.54, 0.67 -0.88 (-1.49, -0.2 0.17 (-0.82, 1.16 0.07 (-0.73, 0.87 0.12 (-0.60, 0.84 -0.30 (-0.70, 0.0 0.28 (-0.21, 0.77 0.00 (-0.58, 0.58 -0.22 (-0.96, 0.5 -0.55 (-1.01, -0.0 -0.58 (-1.15, -0.0 -0.58 (-1.15, -0.0 -1.32 (-2.32, -0.3 0.04 (-0.30, 0.37 0.41 (0.02, 0.80) -0.34 (-0.80, 0.1 0.45 (-0.70, 1.60 -0.59 (-1.75, 0.5 -0.03 (-0.29, 0.2 -0.64 (-1.12, -0.1 -0.01 (-0.96, 0.9 -0.61 (-1.11, -0.1	)         3.09           ?7)         3.08           i)         1.46           ()         2.06           i)         2.43           9)         5.03           ()         4.03           i)         3.27           22)         2.31           99)         4.27           101)         3.37           311)         1.42           ()         5.80           ()         5.08           1)         4.36           ()         1.13           7)         1.11           3)         6.84           (6)         4.11           4)         1.55
Griffin Tang Porter-Starr Bales Mateo-Gallego Wright Raben Subgroup, DL (1 <sup>2</sup> = 43.8%, p = 0.007)	2013 2013 2016 2017 2017 2018 2020	36 22 41 51 29 12	-5.90 (10.34) -7.20 (2.35) -7.60 (6.70) -5.20 (5.20) -5.47 (3.29) -1.90 (1.52) -3.50 (6.30) 2	35 21 26 29 24 10	-2.20 (4.37) -7.60 (1.83) -6.00 (5.60) -5.90 (3.70) -3.65 (4.18) -2.68 (1.81) -3.00 (7.63)		_							-0.46 (-0.94, 0.0 0.19 (-0.41, 0.79 -0.25 (-0.75, 0.2 0.15 (-0.31, 0.60 -0.49 (-1.04, 0.0 0.47 (-0.38, 1.32 -0.07 (-0.25, 0.1 -0.17 (-0.30, -0.0	1) 4.20 )) 3.13 4) 3.99 )) 4.35 6) 3.51 2) 1.87 1) 7.96
Change-from-baseline SD imputed usin Layman Mamo Ferrara Kleiner De Luis Meckling De Luis (wild type group) De Luis (mutant type group) De Luis Subgroup, DL $(l^2 = 0.0\%, p = 0.999)$ Overall, DL Heterogeneity between groups: p = 0.25 $(l^2 = 28.0\%, p = 0.058)$	2003 2005 2006 2006 2007 2007 2009 2009 2009	12 10 7 9 47 10 85 12	-3.05 (9.76) -0.80 (2.21) -1.80 (2.79) -3.00 (10.98) -3.00 (11.05) -5.20 (8.92) -3.00 (10.00) -1.60 (16.46) -2.00 (20.47) 2	10 7 43 8 87 9	-2.60 (7.37) -0.30 (3.55) -0.70 (3.36) -2.40 (11.00) -2.30 (12.53) -3.70 (5.92) -2.20 (12.21) -1.20 (11.53) -3.00 (10.52)	-			-			_		-0.05 (-0.85, 0.7 -0.17 (-1.05, 0.7 -0.35 (-1.38, 0.6 -0.05 (-1.04, 0.9) -0.06 (-0.47, 0.3 -0.19 (-1.13, 0.7 -0.07 (-0.37, 0.2 -0.03 (-0.39, 0.8 0.06 (-0.30, 0.43) -0.05 (-0.23, 0.1) -0.14 (-0.24, -0.0	1) 4.06 7) 2.99 3) 3.21 5) 18.30 4) 3.61 3) 35.04 4) 4.19 i) 23.71 3) 100.00
						-1.5		-1	-0.5	0	0.5	1	1.5		
							Favo	urs higher p	rotein diet		Favours lower	protein diet			

Figure 3. Standardised mean difference (SMD) and 95% confidence interval (CI) in fat mass between the intervention and control groups on the effect of a higher protein diet.

			Intervention	Control			9
sub and author	year	Ν	Mean (SD) N	Mean (SD)	SMD (95% C	l) We	
Change-from-baseline SD imputed using a correl							_
Jenkins	2001	10	-2.00 (9.49) 10	0.00 (11.40)	-0.19 (-1.07,		3.1
Ferrara	2006 2006	7 29	0.80 (5.57) 8	2.90 (7.81)	-0.31 (-1.33, -0.28 (-0.79,		2.3 9.2
Hodgson Kleiner	2000	29	-1.90 (12.37) 31 1.00 (7.81) 7	1.60 (12.95) 3.00 (4.63)	-0.28 (-0.79,		9.4 2.4
Keogh	2000	8	-2.00 (12.96) 5	2.00 (8.06)	-0.35 (-1.38,		1.8
Mecklina	2007	10	-9.00 (16.82) 8	-9.00 (13.11)	0.00 (-0.93, 0		2.7
Abete	2009	9	-13.30 (13.03) 10	-3.00 (8.55)	-0.95 (-1.90,		2.6
De Luis (wild type group)	2009	85	-22.10 (24.76) 87	-13.70 (16.07)	-0.40 (-0.71,	0.10) 26	6.3
De Luis (mutant type group)	2009	12	-1.70 (12.26) 9	-7.50 (13.11)	0.46 (-0.42, 1		3.1
De Luis	2009		-15.00 (16.09) 66		0.06 (-0.30, 0		8.1
Azadbakht	2013	30	-3.66 (12.33) 30	-5.27 (16.22)	0.11 (-0.39, 0		9.3
Jenkins González-Salazar (animal protein intervention)	2014 2020	20 20	-5.00 (10.27) 19 -5.67 (13.35) 19	-4.00 (11.77) -2.69 (10.41)	-0.09 (-0.72, -0.25 (-0.88, -0.25 (-0.		6.0 6.0
González-Salazar (plant protein intervention)	2020	20	-5.67 (9.70) 21	-7.08 (13.10)			6.4
Subgroup, DL	2020	321	-3.07 (3.70) 21	-7.00 (13.10)	-0.16 (-0.32,		
$(l^2 = 0.0\%, p = 0.604)$		021	000			0.01/100	
Change-from-baseline SD reported or obtained fr	om stan	dard (	errors or confidence	e intervals			
Stamets	2004	13	-4.00 (13.00) 13	-3.00 (13.00)	-0.08 (-0.85,		2.2
Appel	2005	82	-9.50 (6.24) 82	-8.20 (6.47)	-0.20 (-0.51,		4.1
Dansinger	2005 2007	40 79	-4.10 (14.00) 40	-4.80 (13.00)	0.05 (-0.39, 0		6.9
Gardner Leidy	2007	21	-3.20 (8.20) 79 -5.00 (9.17) 25	-3.60 (6.90) -3.00 (10.00)	0.05 (-0.26, 0 -0.21 (-0.79,		3.6 3.9
Maki	2007	42	-0.60 (12.96) 42	-1.20 (14.91)	0.04 (-0.38, 0		5.5 7.2
Delbridge	2009	68	4.70 (15.67) 70	6.90 (12.55)	-0.16 (-0.49,		1.9
Aldrich	2011	6	-8.70 (9.55) 6	-2.20 (12.49)	-0.58 (-1.74,		0.9
Gögebakan	2011	105	4.24 (14.27) 92	4.47 (12.81)	-0.02 (-0.30,	J.26) 16	6.9
Te Morenga	2011	37	-5.40 (9.00) 37	-1.70 (8.10)	-0.43 (-0.89,		6.2
Wycherley	2012		-11.00 (10.00) 34	-12.00 (9.00)	0.11 (-0.38, 0		5.6
Tang	2013	22	-11.00 (9.38) 21	-11.00 (9.17)	0.00 (-0.60, 0		3.7
Mateo-Gallego Wright	2017 2018	29 12	-9.35 (16.74) 24 -7.00 (13.00) 10	-4.44 (20.98)			4.5 1.8
Subgroup, DL	2018	587	-7.00 (13.00) 10 575	-2.00 (12.00)	-0.40 (-1.25, -0.09 (-0.21, -0.09 (-0.21, -0.09))		
(l <sup>2</sup> = 0.0%, p = 0.898)		307	515		-0.09 (-0.21,	.02) 100	0.0
Overall, DL		908	905		-0.12 (-0.21,	0.02)	
Heterogeneity between groups: $p = 0.490$ ( $l^2 = 0.0\%$ , $p = 0.883$ )						-	
· · · · · · · · · · · · · · · · · · ·							_
					-1.5 -1 -0.5 0 0.5 1 1.5		

Figure 4. Standardised mean difference (SMD) and 95% confidence interval (CI) in systolic blood pressure between the intervention and control groups on the effect of a higher protein diet.




Figure 5a. Standardised mean difference (SMD) and 95% confidence interval (CI) in total cholesterol between intervention and control groups on the effect of a higher protein diet.

sub and author	year N	Intervention Mean (SD) N	Control Mean (SD)							SMD (95% CI	% Weight
										300 (85% CI	, weight
Change-from-baseline SD reported or obtained from s						- 1				0.00 ( 4.50 0	74) 0.75
Baba		-1.24 (1.15) 6			-					-0.39 (-1.50, 0	
Farnsworth (male population) Farnsworth (female population)		-0.68 (0.56) 7 -0.37 (0.37) 21								-0.83 (-1.93, 0 -0.50 (-1.11, 0	
Aude		-0.47 (1.14) 23								-0.34 (-0.93, 0	
Johnston	2004 22						_			-0.99 (-2.04, 0	
Stamets		-0.33 (0.99) 13								-0.11 (-0.88, 0	
Appel		-0.19 (0.47) 82								-0.41 (-0.72, -	
Dansinger		-0.61 (1.19) 40								-0.57 (-1.02, -	
Luscombe-Marsh	2005 26	-0.62 (1.02) 30	-0.33 (0.66)		_		<b>—</b>			-0.34 (-0.87, 0	.19) 3.27
Noakes		-0.30 (0.72) 48					<b>—</b>			-0.32 (-0.71, 0	
McMillan-Price		-0.19 (0.40) 32			_		<u> </u>			-0.35 (-0.84, 0	
Das		-0.17 (0.28) 15					. •			-0.00 (-0.73, 0	
Gardner		-0.28 (0.60) 79								-0.14 (-0.45, 0	
Leidy		-0.25 (0.52) 25			-			-		-0.23 (-0.81, 0	
Mahon Maki		-0.26 (0.56) 14 -0.28 (0.37) 38								-0.22 (-0.96, 0 -0.36 (-0.82, 0	
Lasker		-0.59 (1.33) 25			_					-0.36 (-0.82, 0	
Abete		-0.05 (0.50) 10				- 1			_	-0.29 (-0.84, 0	
Delbridge		0.27 (0.99) 70				I				-0.13 (-0.46, 0	
Tura		-0.26 (0.64) 6					•			-0.48 (-1.64, 0	
Gögebakan		0.19 (0.51) 93				- I -		_		0.12 (-0.16, 0.	
Te Morenga		-0.31 (0.36) 37			_		_ <b></b>			-0.39 (-0.85, 0	
Wycherley		-0.40 (0.48) 34								0.15 (-0.34, 0.	
Griffin	2013 36	-0.10 (0.30) 35	0.00 (0.15)				-+			-0.43 (-0.90, 0	.04) 4.13
Tang		-1.03 (1.75) 21					—			-0.31 (-0.92, 0	
Mateo-Gallego		-0.06 (0.46) 24					<u> </u>			-0.39 (-0.94, 0	
Wright		-0.30 (0.60) 10	0.10 (0.40)			~	—			-0.77 (-1.64, 0	
Subgroup, DL (1 <sup>2</sup> = 0.0%, p = 0.735)	862	845				~				-0.26 (-0.35, -	0.16)100.00
Change-from-baseline SD imputed using a correlation	coefficient										
Jenkins		-0.27 (0.85) 10		-			<u> </u>			-0.43 (-1.32, 0	
Layman		-0.19 (0.46) 12					_			-0.39 (-1.20, 0	
Moran		-0.35 (0.99) 14								-0.07 (-0.81, 0	
Mamo		-0.10 (0.36) 10			_	_ 1	-			-0.91 (-1.83, 0	
Ferrara	2006 7			-		1	-			-0.29 (-1.31, 0	
Hodgson Kleiner	2006 29 2006 9	-0.05 (1.21) 31 0.08 (0.81) 7								-0.06 (-0.57, 0	
Keogh	2006 9		0.22 (0.72)							-0.18 (-1.17, 0 -0.65 (-1.80, 0	
Meckling			-0.09 (1.14)		_	-				0.12 (-0.81, 1.	
De Luis (wild type group)		-0.06 (0.54) 87				1				0.20 (-0.10, 0.	
De Luis (mutant type group)		0.03 (0.87) 9			_		_		-	-0.01 (-0.88, 0	
De Luis	2009 52	-0.26 (0.85) 66	-0.08 (0.47)				+			-0.27 (-0.64, 0	.09) 14.28
Layman		-0.57 (0.67) 30					-+			-0.45 (-0.93, 0	
Ballesteros-Pomar (people with insulin resistance)	2010 10	-0.43 (0.71) 11	-0.43 (0.64)		_		•		-	0.00 (-0.86, 0.	
Ballesteros-Pomar (people without insulin resistance)						-				-0.60 (-1.64, 0	
Azadbakht		-0.08 (0.43) 30					-			-0.02 (-0.53, 0	
Jenkins		-0.73 (1.14) 19						_		-0.25 (-0.88, 0	
Kim González-Salazar (animal protein intervention)	2017 6 2020 20	0.04 (0.71) 6							-	-0.30 (-1.44, 0 -0.20 (-0.83, 0	
Gonzalez-Salazar (animal protein intervention) González-Salazar (plant protein intervention)		-0.65 (0.74) 19 -0.54 (0.87) 21			_					-0.20 (-0.83, 0	
Subgroup, DL	2020 20		-0.32 (0.80)			~	>			-0.15 (-0.29, -	
(1 <sup>2</sup> = 0.0%, p = 0.820)	415	410				-				-0.10 (-0.28, -	
Overall, DL	1275	1255								-0.22 (-0.30, -	14)
Heterogeneity between groups: p = 0.216	1270	1200				$\checkmark$				-0.22 (-0.30, -	
(1 <sup>2</sup> = 0.0%, p = 0.855)											
				-1.5	-1	-0.5	0	0.5	1	1.5	
					Favours high			Favours lower p			

Figure 5b. Standardised mean difference (SMD) and 95% confidence interval (CI) in triacylglycerol between intervention and control groups on the effect of a higher protein diet.

sub and author	year	N	Intervention Mean (SD) N	Contro Mean (SE									SMD (95% CI)	% Weight
	year	IN .	Wealt (SD)	Mean (St	"			_					SWD (85 % CI)	weight
Change-from-baseline SD reported or obtained from sta								.	_				0.05 / 0.75 4.45	
Baba Farnsworth	1999 2003	7 28 -	0.10 (0.05) 6						-			_	0.35 (-0.75, 1.45 0.07 (-0.45, 0.59	
Johnston	2003		32.64 (33.18) 7										-0.03 (-1.02, 0.9	
Dansinger		-	42.60 (72.00) 40				_	47					-0.56 (-1.01, -0.1	
Luscombe-Marsh			39.00 (46.74) 30					÷					-0.54 (-1.07, -0.0	
Noakes			16.20 (21.66) 48					i –					-0.22 (-0.61, 0.1)	
McMillan-Price			10.40 (38.47) 32	-13.30 (39.0	3)			1					0.07 (-0.41, 0.56	ý 4.72
Das			15.42 (12.12) 15					1					-0.38 (-1.11, 0.36	
Gardner			11.40 (28.20) 79			_	_	1					-0.54 (-0.86, -0.2	
Maki			-2.40 (41.22) 39		*			1	_				-0.19 (-0.63, 0.2)	
Tura	2010 2011 1		-6.00 (24.00) 6 9.06 (26.58) 106			_			-				0.25 (-0.89, 1.39	
Goyenechea Wycherley		24 32 -	26.04 (40.98) 34										0.08 (-0.18, 0.33	
Gadqil			-0.36 (27.90) 80					-					0.07 (-0.24, 0.38	·
Griffin			10.20 (27.48) 35						_				-0.20 (-0.66, 0.2)	
Tang	2013	22 -	32.40 (33.78) 21	-22.20 (38.5)		_		-1					-0.28 (-0.88, 0.3)	
Raben		35	-2.88 (6.77) 240		6)		_						-0.16 (-0.34, 0.0	
Subgroup, DL	8	63	847	,			<	2					-0.17 (-0.28, -0.0	5) 100.00
(l <sup>°</sup> = 17.4%, p = 0.250)								i l						
Change-from-baseline SD imputed using a correlation of	coefficient							1						
Moran			45.60 (48.54) 14				_		_				-0.50 (-1.25, 0.2	
Mamo		10	10.80 (5.52) 10					:+	-	-			0.87 (-0.05, 1.79	
Hodgson		29	6.60 (76.56) 31										0.17 (-0.34, 0.68	
Kleiner Keogh	2006 2007	9 8 -	0.00 (0.19) 7					1					0.01 (-0.98, 1.00 0.05 (-1.07, 1.17	
Meckling		-	18.60 (31.44) 8					1			_		-0.29 (-1.22, 0.6	·
Abete	2009		35.40 (41.04) 10				-						-0.79 (-1.73, 0.1	.,
De Luis (wild type group)	2009		30.00 (73.62) 87			-	-	+					0.07 (-0.23, 0.37	
De Luis (mutant type group)	2009		20.40 (56.76) 9	-15.60 (37.4	4)					_			-0.10 (-0.96, 0.7)	7) 3.73
De Luis			43.20 (52.32) 66						· _				-0.17 (-0.54, 0.1	
Ballesteros-Pomar (people with insulin resistance)			45.00 (52.86) 11					+	_				0.51 (-0.36, 1.38	
Ballesteros-Pomar (people without insulin resistance) Jenkins	2010 2014		-9.00 (25.98) 7 (14.00 (23.96) 19						-				0.27 (-0.75, 1.29	
Subgroup, DL		20 -	284					2					-0.02 (-0.04, 0.0	·
$(l^2 = 0.0\%, p = 0.500)$	2		204	r									-0.00 (-0.17, 0.16	, 100.00
								1						
Overall, DL	11	39	1131				•						-0.12 (-0.22, -0.0	3)
Heterogeneity between groups: $p = 0.115$ ( $1^2 = 12.8\%$ , $p = 0.268$ )														
(, intervite = 0.000)					_			_						
					-1.5	-1	-0.5	0	0.5			1.5		
					-1.5	-1	-0.5	0	0.5	1		1.5		
						Favours higher p	orotein diet		Favours	lower pro	otein diet			

Figure 6. Standardised mean difference (SMD) and 95% confidence interval (CI) in fasting insulin between intervention and control groups on the effect of a higher protein diet.

Pre-proof